Related Experiment Video

Updated: Dec 21, 2025

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants
07:38

Intracellular Phosphoflow Cytometry of Acute Myeloid Leukemia Patient-Derived Xenotransplants

Published on: June 6, 2025

549

Towards a Personalized Treatment of Patients with Chronic Myeloid Leukemia

Florence Rabian1, Etienne Lengline2, Delphine Rea2,3,4

  • 1Service Hématologie Adolescents et Jeunes Adultes, Hôpital Saint-Louis, Avenue Claude Vellefaux, 75010, Paris, France. florence.rabian@aphp.fr.

Current Hematologic Malignancy Reports
|November 25, 2019
PubMed
Abstract

Insights

Treatment-free remission is now possible for some chronic myeloid leukemia patients. Personalized treatment choices with tyrosine kinase inhibitors (TKIs) improve outcomes and quality of life.

Area of Science:

  • Oncology
  • Hematology
  • Pharmacology

Background:

  • The advent of BCR-ABL tyrosine kinase inhibitors (TKIs) has transformed chronic myeloid leukemia (CML) management.
  • First-generation imatinib, followed by second-generation (dasatinib, nilotinib, bosutinib) and third-generation (ponatinib) TKIs, expanded therapeutic options.
  • CML patients now experience near-normal life expectancy and improved quality of life with lifelong TKI treatment.

Purpose of the Study:

  • To review the evolving treatment landscape for CML.
  • To discuss tailoring TKI selection based on individual patient characteristics.
  • To highlight the possibility of achieving treatment-free remission under specific conditions.

Main Methods:

  • Review of clinical data and therapeutic advancements in CML treatment.
  • Analysis of TKI efficacy, safety profiles, and resistance mechanisms.
  • Discussion of personalized medicine approaches in CML management.

Main Results:

  • TKIs have revolutionized CML outcomes, offering effective treatment for intolerance and resistance.
  • Personalized TKI selection, considering safety profiles and patient background, is crucial.
  • Treatment-free remission is an achievable goal for select CML patients.

Conclusions:

  • Modern TKIs have significantly improved CML patient survival and quality of life.
  • Individualized treatment strategies are essential for optimizing CML management.
  • The potential for treatment-free remission represents a major advancement in CML therapy.
Keywords:
Chronic myeloid leukemiaPersonalized medicineTyrosine kinase inhibitors

More Related Videos

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up09:01

Flow Cytometry to Estimate Leukemia Stem Cells in Primary Acute Myeloid Leukemia and in Patient-derived-xenografts, at Diagnosis and Follow Up

Published on: March 26, 2018

14.5K
Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia09:57

Comprehensive Protocol to Sample and Process Bone Marrow for Measuring Measurable Residual Disease and Leukemic Stem Cells in Acute Myeloid Leukemia

Published on: March 5, 2018

30.2K

Related Concept Videos

Combination Therapies and Personalized Medicine02:50

Combination Therapies and Personalized Medicine

Combining two or more treatment methods increases the life span of cancer patients while reducing damage to vital organs or tissue from the overuse of a single treatment. Combination therapy also targets different cancer-inducing pathways, thus reducing the chances of developing resistance to treatment.
The combination of the drug acetazolamide and sulforaphane is a good example of combination therapy to treat cancer. The cells in the interior of a large tumor often die due to the hypoxic and...
5.8K
Targeted Cancer Therapies02:57

Targeted Cancer Therapies

The targeted cancer therapies, also known as “molecular targeted therapies,” take advantage of the molecular and genetic differences between the cancer cells and the normal cells. It needs a thorough understanding of the cancer cells to develop drugs that can target specific molecular aspects that drive the growth, progression, and spread of cancer cells without affecting the growth and survival of other normal cells in the body.
There are several types of targeted therapies against...
8.5K
Stem Cell Therapy for Tissue Regeneration01:21

Stem Cell Therapy for Tissue Regeneration

Stem cell therapy is a method used in regenerative medicine to repair and restore function to damaged tissues and organs. Stem cells have the potential to proliferate and differentiate into various tissue types, making them ideal candidates for tissue regeneration. For example, hematopoietic stem cell transplants are commonly used in blood cancer treatment to replenish damaged bone marrow and restore healthy blood cells.
Types of Stem Cells used in Stem Cell Therapy
The two main cell...
4.5K
Treatment Resistant Cancers02:56

Treatment Resistant Cancers

Cancer is the second leading cause of death in the United States. A cancer cell is genetically unstable and hence can mutate faster. They can also modify their microenvironment and escape immune surveillance. The difficulties in treating cancer are further compounded by the emergence of rapid resistance to anticancer drugs. The most common ways to attain resistance in cancer cells include alteration in drug transport and metabolism, modification of drug target, elevated DNA damage response, or...
3.6K
Bone Marrow Sampling and Transplants01:22

Bone Marrow Sampling and Transplants

Bone marrow transplant is a potential cure for several diseases, including cancer and specific genetic disorders. Notably, this procedure is applicable for patients suffering from aplastic anemia, certain types of leukemia, severe combined immunodeficiency disease (SCID), Hodgkin's disease, non-Hodgkin's lymphoma, multiple myeloma, thalassemia, sickle-cell disease, and certain cancers.
The transplant begins with high doses of chemotherapy and radiation treatment, which aim to destroy...
728